Puma Biotechnology Inc (PBYI) Stock Analysis
Verdict: WATCH (do not buy)
Profitable commercial-stage oncology model with 8.3% FCF yield faces multi-year EPS declines and heavy insider selling.
Investment score: 58/100
Analysis as of
Is Puma Biotechnology Inc stock worth reviewing? The TradeMates thesis
Puma Biotechnology combines solid short-term profitability ($41.7M FCF in 2025) with long-term revenue stagnation and insider selling, rendering the stock a Hold near 52-week highs.
7-factor investment score
- Valuation: 65/100 (weight 20%)
- Financial Health: 60/100 (weight 15%)
- Technical Momentum: 70/100 (weight 15%)
- Earnings Quality: 85/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 30/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Puma Biotechnology Inc opportunities and risks
What speaks for PBYI
- Pipeline Expansion via Alisertib Phase II Trial
What speaks against PBYI
- Long-Term Top-Line Stagnation and EPS Decline
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| PBYI | 18.1x | 2.1x | 9.7x | 74.8% | 11.6% | 8.3% |
| RGNX | n/a | 2.3x | n/a | 54.2% | -112.6% | -62.6% |
| ZURA | n/a | 0.0x | n/a | 0.0% | 0.0% | -19.2% |
| TECX | n/a | 0.0x | n/a | 0.0% | 0.0% | -15.0% |
| ASMB | 44.6x | 6.5x | 6705.4x | 77.7% | -0.1% | -7.9% |
| Peer median | n/a | 1.1x | n/a | 27.1% | -0.0% | -17.1% |
Frequently asked questions about Puma Biotechnology Inc (PBYI)
Is PBYI stock a good investment?
The TradeMates model rates Puma Biotechnology Inc as WATCH (do not buy) with an investment score of 58/100. Puma Biotechnology combines solid short-term profitability ($41.7M FCF in 2025) with long-term revenue stagnation and insider selling, rendering the stock a Hold near 52-week highs. This is algorithmic model output, not personal investment advice.
Is PBYI stock a buy?
The TradeMates model verdict for PBYI is WATCH (do not buy) with an investment score of 58/100. Treat this as a model signal to review, not a personal buy recommendation.